Business Context and Reporting Period
Company: MiMedx Group, Inc. (MDXG)
Filing Type: Form 8-K (Current Report)
Date of Report: July 29, 2026
Event: Entry into a Material Definitive Agreement (Agreement and Plan of Merger) with Sanara MedTech Inc. ("Sanara").
On July 29, 2026, MiMedx entered into a merger agreement to acquire Sanara. Upon closing, a wholly-owned subsidiary of MiMedx will merge with and into Sanara, with Sanara surviving as a wholly-owned subsidiary of MiMedx. The transaction has been unanimously approved by the boards of directors of both companies.
Key Financial Metrics and Transaction Terms
Merger Consideration:
- Cash Component: $33.00 per share of Sanara common stock.
- Stock Component: 0.4735 shares of MiMedx Common Stock per share of Sanara common stock.
- Valuation Basis: The stock component represents a value of $2.00 per share, calculated based on the average closing price of MiMedx stock for the five trading days prior to July 29, 2026.
Financing:
- MiMedx secured a debt commitment letter from funds managed by Hayfin Capital Management LLP.
- Facility Size: $300.0 million first lien senior secured term loan.
- Use of Proceeds: To fund the cash portion of the merger consideration and repay MiMedx's existing credit agreement in full.
Termination Fees:
- Sanara Termination Fee: $22,540,785.00 payable to MiMedx under specific circumstances (e.g., Sanara terminating for a superior proposal or changing recommendation).
- MiMedx Termination Fee: $9,660,336.00 payable to Sanara if MiMedx fails to consummate the merger when required.
Historical Financials: The filing text does not provide specific revenue, profit, cash flow, or margin figures for MiMedx or Sanara for the current or prior periods.
Material Changes and Transaction Structure
This filing represents a material change in corporate structure and strategy through the proposed acquisition of Sanara. Key structural elements include:
- Equity Treatment: Sanara equity awards (restricted stock and options) will be converted into cash and MiMedx stock consideration immediately prior to the effective time.
- Voting Support: MiMedx entered into a Voting Agreement with Sanara and certain "Specified Stockholders" holding approximately 38.9% of Sanara's voting power, agreeing to vote in favor of the merger.
- End Date: The merger must be consummated by July 29, 2027, extendable to January 29, 2028 if antitrust approvals are pending.
Guidance, Outlook, Risks, and Contingencies
Outlook and Management Commentary:
- Management expects the merger to result in combined surgical revenue and Adjusted EBITDA margin improvements, though specific numerical guidance is not provided in this text.
- Forward-looking statements regarding synergies and future performance are subject to substantial risks and uncertainties.
Conditions to Closing:
- Approval by a majority of Sanara stockholders.
- SEC effectiveness of the Form S-4 registration statement.
- Expiration of Hart-Scott-Rodino antitrust waiting periods.
- Absence of laws or injunctions prohibiting the merger.
- No Material Adverse Effect on Sanara since the agreement date.
Risks and Contingencies:
- Regulatory Risk: Potential delays or denial of FDA approvals for products and antitrust clearance.
- Market Risk: Dependence on reimbursement environments, competition, and macroeconomic factors.
- Execution Risk: Failure to realize anticipated synergies or integration challenges.
- Financing Risk: Adverse developments in credit markets affecting the ability to secure the $300 million debt facility.
Important Facts for Investor Verification
- Consideration Mix: Verify the final value of the stock component at closing, as it is tied to MiMedx's stock price on the last trading day prior to the closing date.
- Financing Conditions: Confirm the execution of definitive documentation for the $300 million debt facility and the repayment of MiMedx's existing credit agreement.
- Stockholder Approval: Monitor the outcome of the Sanara stockholder vote required to approve the merger.
- Regulatory Approvals: Track the status of antitrust reviews (HSR Act) and any necessary regulatory clearances for the combined entity's products.
- Termination Triggers: Review the specific conditions under which the $22.5 million or $9.7 million termination fees would be triggered.
- Proxy Statement: Review the upcoming Form S-4 registration statement/proxy statement for detailed financial projections and risk factors not fully detailed in this 8-K.